EU Pharma Reorg Leaves Questions About How R&D Will Be Supported
Responsibility for setting pharmaceutical policy across the European Union shifted in late November from the European Commission's Enterprise & Industry department to its Health department
You may also be interested in...
Patient rights to access information on prescription drugs could mean that industry should be permitted to provide data, says a draft EU report.
Tackling counterfeit drugs is one pillar of the European Commission's package of new proposed pharmaceutical legislation. It will mean higher costs for most drug firms, while significant loopholes will remain
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011